UTIBRON

Drug Sunovion Pharmaceuticals Inc.
Total Payments
$4.7M
Transactions
59,811
Doctors
16,232
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2020 $1,257 15 0
2019 $3,029 15 0
2018 $544,752 5,582 2,833
2017 $4.1M 54,199 15,134

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2.8M 1,223 60.6%
Food and Beverage $796,956 47,899 17.0%
Travel and Lodging $651,655 3,363 13.9%
Unspecified $358,102 123 7.6%
Consulting Fee $24,673 7 0.5%
Education $19,638 7,196 0.4%

Payments by Type

General
$4.3M
59,688 transactions
Research
$358,102
123 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE Novartis Pharmaceuticals Corporation $346,822 0
A 12 WEEK TREATMENT MULTI CENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF QVA149 INDACATEROL MALEATE AND OR GLYCOPYRRONIUM BROMIDE IN COPD PATIENTS WITH MODERATE TO SEVERE AIRFLOW LIMITATION Novartis Pharmaceuticals Corporation $6,993 0
A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONA Novartis Pharmaceuticals Corporation $4,286 0

Top Doctors Receiving Payments for UTIBRON

Doctor Specialty Location Total Records
Unknown — Boston, MA $366,300 125
, MD Pulmonary Disease Long Beach, CA $124,872 203
, MD Critical Care Medicine Jamaica, NY $95,382 134
, MD Pulmonary Disease Westminster, CA $92,483 151
Carlos Araujo-Preza — The Woodlands, TX $84,747 145
, MD Critical Care Medicine Oakland Park, FL $82,890 99
, M.D Pulmonary Disease Lebanon, NH $82,241 140
, MD, FCCP Critical Care Medicine South Boston, VA $72,134 81
, MD Pulmonary Disease Denver, CO $68,626 63
, M.D Pulmonary Disease Fountain Valley, CA $62,652 103
, MD Specialist Somerset, KY $60,405 138
, M.D Geriatric Medicine Hendersonville, TN $56,680 124
, M.D Specialist Panama City, FL $51,397 67
, MD MCPS FACP FCCP Pulmonary Disease Ada, OK $50,285 99
, MD Critical Care Medicine Jackson, MS $46,944 77
Israel Rubinstein Critical Care Medicine Chicago, IL $41,507 75
Javier Perez-Fernandez Critical Care Medicine South Miami, FL $40,007 80
, DO Internal Medicine Philadelphia, PA $38,681 85
, MD Critical Care Medicine Lafayette, IN $38,483 56
, MD Pulmonary Disease San Antonio, TX $34,371 43
, M.D Pulmonary Disease Saint Louis, MO $33,487 69
, MD Family Medicine Orange, CA $32,433 65
, MD Critical Care Medicine Kissimmee, FL $30,563 87
, M.D Pulmonary Disease Miami, FL $30,501 54
, M.D Pulmonary Disease Tualatin, OR $30,230 69
123…650»

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $4.7M
  • Total Doctors 16,232
  • Transactions 59,811

About UTIBRON

UTIBRON is a drug associated with $4.7M in payments to 16,232 healthcare providers, recorded across 59,811 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..

Payment data is available from 2017 to 2020. In 2020, $1,257 was paid across 15 transactions to 0 doctors.

The most common payment nature for UTIBRON is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.8M, 60.6% of total).

UTIBRON is associated with 3 research studies, including "A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE" ($346,822).